Q1 Earnings Forecast for Rezolute Issued By HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Rezolute in a research report issued on Thursday, February 13th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings per share of ($0.33) for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.40) EPS.

Other equities research analysts also recently issued research reports about the stock. Craig Hallum raised shares of Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Wedbush reissued an “outperform” rating and issued a $112.00 price objective on shares of Rezolute in a research report on Monday, November 4th. Guggenheim restated a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Finally, JMP Securities increased their price target on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday, February 13th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Rezolute has an average rating of “Buy” and a consensus target price of $24.38.

Rezolute Stock Up 3.5 %

Shares of RZLT opened at $4.77 on Monday. The business has a fifty day moving average of $4.85 and a 200 day moving average of $4.90. The company has a market cap of $276.37 million, a PE ratio of -3.76 and a beta of 1.10. Rezolute has a 52-week low of $1.41 and a 52-week high of $6.19.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11.

Insider Transactions at Rezolute

In other news, CFO Daron Evans bought 10,000 shares of the stock in a transaction on Wednesday, December 18th. The stock was acquired at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the acquisition, the chief financial officer now owns 150,900 shares of the company’s stock, valued at $647,361. This represents a 7.10 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 18.39% of the company’s stock.

Hedge Funds Weigh In On Rezolute

Several institutional investors have recently made changes to their positions in RZLT. JPMorgan Chase & Co. bought a new position in shares of Rezolute during the third quarter valued at approximately $42,000. Alpine Global Management LLC acquired a new stake in shares of Rezolute in the 4th quarter worth $54,000. MML Investors Services LLC purchased a new stake in shares of Rezolute during the third quarter worth about $57,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Rezolute during the 3rd quarter valued at approximately $65,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock valued at $112,000 after purchasing an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.